GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation Q4 FY 23-24 and FY 23-24.24-05-2024
24-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith press release and management discussion & analysis for the quarter and year ended March 31, 202424-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Corporate Action-Board to consider Dividend
The Board has recommended dividend @ 250% i.e. Rs. 2.5/- per share (face value of Re. 1/-) on the equity shares of the Company for FY 2023-24, subject to approval of the shareholders at the ensuing Annual General Meeting.24-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Appointment Of Cost Auditor For FY 24-25
The Board has approved the appointment of M/s. RA & Co., Cost Auditor of the Company for FY 2024-25.24-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Outcome for Financial Results And Declaration Of Dividend
Please find enclosed financial results for the quarter and year ended March 31, 2024 along with recommendation of dividend.24-05-2024
Glenmark to bring into India, two cancer drugs from BeiGene
Alok Malik, Glenmark Pharmaceuticals' President and Business Head (India Formulations) said, the addition of the two oncology drugs would help provide access to novel therapies across India.21-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India21-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Glenmark Pharmaceuticals Limited will host an 'Investor Day 2024' from 16:30 to 18:30 IST (07:00 to 09:00 EDT) on Thursday, 30 May 2024, in Mumbai. The senior management team of Glenmark will be presenting the Company's growth plans to Investors and Research Firms.17-05-2024
Glenmark Pharmaceuticals Gets USFDA Approval For Ophthalmic Solution
Glenmark Pharmaceuticals receives final USFDA approval for its generic ophthalmic solution used in treating increased eye pressure caused by glaucoma or other conditions.17-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Opthalmic Solution, 0.2% / 0.5%17-05-2024